← Patent-cliff monitor small molecule VEKLURY REMDESIVIR
Loss of exclusivity November 2041 latest FDA-listed patent expiry
Drug detail Brand name VEKLURY Active ingredient REMDESIVIR Strength 100MG/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval October 2020 Marketing status RX
Listed patents Patent Expires Type 11491169*PED November 2041 — 11975012*PED November 2041 — 11903953*PED November 2041 — 11975012 May 2041 use U-3836 11491169 May 2041 use U-3835 11903953 May 2041 use U-3836 11975017*PED January 2039 — 11266681*PED January 2039 — 10675296*PED January 2039 — 11975017 July 2038 product 11266681 July 2038 use U-3831 10675296 July 2038 product 11007208*PED March 2037 — 11382926*PED March 2037 — 10695361*PED March 2037 — 11382926 September 2036 use U-3832 11007208 September 2036 use U-3832 10695361 September 2036 use U-3832 9724360*PED April 2036 — 9949994*PED April 2036 — 9724360 October 2035 substance, product 9949994 October 2035 substance 10065958*PED May 2033 — 10065958 November 2032 substance 11492353*PED June 2032 — 11492353 December 2031 substance 8008264*PED March 2030 — RE46762*PED October 2029 — 8318682*PED October 2029 — 8008264 September 2029 substance, product 8318682 April 2029 substance, product RE46762 April 2029 substance, product
Regulatory exclusivity Code Expires PED January 2027 M-301 July 2026 PED April 2026 NCE October 2025
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.